Last reviewed · How we verify
NCT05692518
MagDI Diversion Feasibility Study
NA trial testing MAGNET System, DI Bio-fragmentable in Type 2 Diabetes in 15 participants. Completed in 20 May 2025.
23 August 2024
Quick facts
| Lead sponsor | GT Metabolic Solutions, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 15 |
| Start date | 19 December 2022 |
| Primary completion | 23 August 2024 |
| Estimated completion | 20 May 2025 |
| Sites | 1 location across Georgia |
Drugs / interventions tested
- MAGNET System, DI Bio-fragmentable
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Obesity — all drugs for Obesity →
Sponsor
GT Metabolic Solutions, Inc.
Who can join
Adults 18 to 65, any sex, with Type 2 Diabetes or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical research study is to evaluate the feasibility of the GT Metabolic Solutions DI Bio-fragmentable Magnetic Anastomosis System (MAGNET System, DI Bio-fragmentable) for creation of a side-by-side anastomosis duodeno-ileostomy in obese adults.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
First-in-Human Side-to-Side Duodenoileal Bipartition for Weight Loss and Type 2 Diabetes with the Swallowable Biofragmentable Magnetic Anastomosis System.
Gagner M, Abuladze D, Buchwald J, Koiava L, et al · · 2025 · cited 4× · PMID 40062584 · DOI 10.1097/xcs.0000000000001384
Verify or expand the search:
- PubMed search for NCT05692518
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other GT Metabolic Solutions, Inc. trials
Trials by the same sponsor.
- NCT07085741 — Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosi · NA · active not recruiting
- NCT06613724 — Magnetic Duodeno-Ileal Chile Study · NA · completed
- NCT06473831 — MagDI Australia Study · NA · active not recruiting
- NCT06232746 — Magnetic Jejuno-Ileal Diversion Study ("MJI Study") · NA · completed
- NCT05322122 — Creation of Side-to-Side Compression Anastomosis Using the Magnetic Anastomosis System · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05692518 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GT Metabolic Solutions, Inc.
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05692518.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing